ArticleProceedings of the National Academy of Sciences of the United States of America1998
Targeted expansion of genetically modified bone marrow cells.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 72 citations in OpenAlex.
- Evolving insights into the synergy between erythropoietin and thrombopoietin and the bipotent erythroid/megakaryocytic progenitor cell.Experimental hematology · 2016Review
- Engineering macrophages to control the inflammatory response and angiogenesis.Experimental cell research · 2015Article
- Article
- A cell-based high-throughput screen for novel chemical inducers of fetal hemoglobin for treatment of hemoglobinopathies.PloS one · 2014Article
- Long-term regulation of genetically modified primary hematopoietic cells in dogs.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Gene therapy of MPL deficiency: challenging balance between leukemia and pancytopenia.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
- Congenital amegakaryocytic thrombocytopenia and thrombocytopenia with absent radii.Hematology/oncology clinics of North America · 2009Review
- New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition.Leukemia · 2008Article
- Using gene transfer to circumvent off-target effects.Gene therapy · 2008Review
- Expansion of multipotent and lymphoid-committed human progenitors through intracellular dimerization of Mpl.Blood · 2008Article
- Article
- Article
- JAK2, complemented by a second signal from c-kit or flt-3, triggers extensive self-renewal of primary multipotential hemopoietic cells.The EMBO journal · 2002Article
- Hematopoietic stem cell gene therapy.International journal of hematology · 2002Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
The ability to specifically target a mitogenic signal to a population of genetically modified primary cells would have potential applications both for gene and cell therapy. Toward this end, a gene encoding a fusion protein containing the FK506-binding protein FKBP12, fused to the intracellular portion of the receptor for thrombopoietin (mpl), was introduced into primary murine bone marrow cells. Dimerization of this fusion protein through the addition of a dimeric form of the drug FK506, called FK1012, resulted in a marked proliferative expansion of marrow cells that was restricted to the genetically modified population. FK1012's proliferative effect was sustained and reversible. An apparent preference for differentiation along the megakaryocytic lineage was observed. This approach allows for the specific delivery of a mitogenic signal to a population of genetically modified primary cells and may have applications for studies in hematopoiesis and receptor biology, and for gene and cell therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.